|
A new addition for your endometritis
treatment plans
Endometritis is an important disease with significant economic
impact to the horse industry. It is estimated that this non-life
threatening disease affects up to 43% of broodmares worldwide.
During the 2004 breeding season, cultures performed at Hagyard-Davidson-McGee
found Streptococcus zooepidemicus the most prevalent uterine pathogen.
Following extensive research over 4 breeding seasons, the USDA has approved
SETTLE as an aid in the treatment of equine endometritis caused by
Streptococcus zooepidemicus. Powerful as a stand-alone therapy,
SETTLE can be effectively integrated with standard treatment regimens
that include antibiotics and uterine lavage.
Flexible Administration
Both intravenous and intrauterine administration routes demonstrated
strong efficacy. SETTLE can
be used as best fits the specific mare
without compromising results. This flexibility allows SETTLE to be
easily added into established therapy plans, making it a practical
addition for most broodmare operations.
Small Addition, Big Benefit
If you treat endometritis the same way as last year, can you really
expect any better results?
This season, one simple addition to your treatment plans offers the
opportunity to improve your results. SETTLE is a safe and efficacious
therapy with practical administration options. Not just more
antibiotics and uterine lavage - now you have a new tool to enhance
treatment and SETTLE the mare. |
 |
Extensive studies with
SETTLE have evaluated its mode of action and
indications for use.
These studies have
demonstrated that SETTLE is beneficial in treating uterine bacterial
infections and the inflammatory responses associated with infection,
trauma or breeding.
Click for more information...
|
